BioCision
the coolprep
TM company, today announced the release of three new
cryopreservation systems:
CoolCell® FTSTM30, the first
large-capacity, high-density cell freezing system;
CoolCell SV2 for freezing cells in larger diameter 2ml vials; and
CoolCell 5ml for large cryovial freezing. All CoolCell freezing
solutions deliver a controlled freezing rate of -1
oC/minute in a -80
oC
freezer, with high reproducibility of freezing profiles and consistent cell
viability and function after thawing. The patented alloy-based technology
allows maintenance-free operation and is a significant alternative to
conventional freezing methods or programmable freezers.
"In many areas of
biological research, the ability to freeze and thaw samples of cells is
absolutely critical to successful experiments. Yet, all too often, this simple
procedure is subject to considerable and unnecessary variation, as well as high
cost. CoolCell FTS30 solves this problem," said Brian Schryver, BioCision's
Vice President of Research and Development. "Selling for a fraction of the
price of commercial cell cryopreservation devices and sized to fit compactly
inside any -80
oC freezer, this new CoolCell makes a powerful
research tool available to all scientists."
CoolCell FTS30 uses a
patented alloy-based micro-convection heat removal technology to uniformly
freeze 30-vial batches in a compact space. It is ideal for all cells
including cell lines, stem cells, yeast, blood and other primary cells. The
durable, insulated design of the CoolCell FTS30 ensures easy and safe
portability of frozen cells, insertion and removal of 30 vials at once, and
lids that open easily even when frozen.
CoolCell FTS30 Features:
-
Ideal for all cells including cell lines, stem cells,
PBMC, primary cells and yeast
- Can be used "off the shelf" without any maintenance or
pre-cooling
- Prepares samples for archive storage in four hours
- Sized to fit compactly inside any -80oC
freezer
- Holds 30 screw-cap 2ml cryotubes
- An inner removable FTS vial module enables efficient
freezing, transfer, and storage of vials in just one step
More CoolCell Solutions
Along with CoolCell FTS30, BioCision is introducing
two additional products: (1) CoolCell SV2 for freezing larger diameter 2ml
vials, such as Crystal Zenith®1 vials for freezing dendritic cells
and other cells used in basic and clinical research applications; and (2)
CoolCell 5ml for large-volume cryovials. Like all other CoolCell products, these
two new additions are also maintenance-free, require no alcohol and deliver
rate-controlled cell freezing of -1oC/minute in a -80oC
freezer.
"The launch of these
CoolCell products marks the beginning of a significant expansion of our cell
cryopreservation product line," said BioCision CEO Rolf Ehrhardt, MD, PhD. "We
will be releasing additional sample cryopreservation products over the coming
months to meet the growing demands of cell research, cell therapy, and the
diagnostic market. Our goal is to continue to deliver both performance and
simplicity for sample handling and cryopreservation."
CoolCell FTS30 cell
freezing system, CoolCell SV2 and CoolCel 5ml are available for pre-order now
and will begin shipping July 15, 2011.
1 Crystal Zenith
® is a registered
trademark of Daikyo Seiko, Ltd.
About BioCision
BioCision® is the leading global developer of benchtop sample
and assay management tools.
The company's
patent-pending products enable collection, organization, protection, freezing,
thawing, cooling and cryopreservation of samples in a consistent and highly
reproducible manner. BioCision's line of benchtop tools include CoolRack
®,
CoolSink
TM and CoolTray
TM thermo-conductive tube and plate
modules; CoolBox
TM ice-free portable cooling/freezing containers;
CoolCell
® alcohol-free maintenance-free cell freezing containers;
and accessories.
The advantages of
ease-of-use, elimination of user error, and highly reproducible performance
have made BioCision's products the new standard for benchtop sample management.
BioCision's products are sold worldwide through distributors in more than two dozen countries in all major
geographic regions. They have been adopted by leading pharmaceutical and
biotechnology companies, contract research organizations and major academic and
healthcare institutions worldwide.
Headquartered in Mill Valley, California,
USA, BioCision
was founded in 2007 by a group of scientists, biomedical engineers and drug
development experts. For more information, visit
www.biocision.com.